Abstract
There is increasing evidence to support the idea that immune modulation is involved in cancer progression. Indeed, the growth in the number of publications describing cancer immunotherapy and how it impacts on cell signaling pathways reinforces this idea. In particular, the forkhead box P3 (Foxp3) transcription factor is an important protagonist in regulatory T cell (Treg) suppression, which has recently been reported to be mediated by the PI3-kinase/AKT/mTOR and TGF-β signaling cascades. This could provide an exciting facet of carcinogenesis, by linking modulation of immuneeffector cells and tumourogenesis of cancer cells. Furthermore, recent findings have indicated a direct role for Foxp3 within tumour cells, and its expression in Tregs has been used as an indicator of poor prognosis in cancer patients. Therapeutic modulation of these systems thus provides an attractive approach to cancer treatment. Additionally, drugcombination strategies utilising agents that target signaling pathways may prove beneficial by simultaneously targeting tumour and immune cells, thereby enhancing native immune response to growing tumours. This article will review the factors involved in Foxp3 expression and highlight the means by which Foxp3-expressing cells could be targeted as a part of cancer immunotherapy.
Keywords: Foxp3, regulatory T cell, cancer, signaling, target, therapy
Current Signal Transduction Therapy
Title: The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Volume: 4 Issue: 2
Author(s): Brendan Meyer, Wai M. Liu, Angus G. Dalgleish and Christine Galustian
Affiliation:
Keywords: Foxp3, regulatory T cell, cancer, signaling, target, therapy
Abstract: There is increasing evidence to support the idea that immune modulation is involved in cancer progression. Indeed, the growth in the number of publications describing cancer immunotherapy and how it impacts on cell signaling pathways reinforces this idea. In particular, the forkhead box P3 (Foxp3) transcription factor is an important protagonist in regulatory T cell (Treg) suppression, which has recently been reported to be mediated by the PI3-kinase/AKT/mTOR and TGF-β signaling cascades. This could provide an exciting facet of carcinogenesis, by linking modulation of immuneeffector cells and tumourogenesis of cancer cells. Furthermore, recent findings have indicated a direct role for Foxp3 within tumour cells, and its expression in Tregs has been used as an indicator of poor prognosis in cancer patients. Therapeutic modulation of these systems thus provides an attractive approach to cancer treatment. Additionally, drugcombination strategies utilising agents that target signaling pathways may prove beneficial by simultaneously targeting tumour and immune cells, thereby enhancing native immune response to growing tumours. This article will review the factors involved in Foxp3 expression and highlight the means by which Foxp3-expressing cells could be targeted as a part of cancer immunotherapy.
Export Options
About this article
Cite this article as:
Meyer Brendan, Liu M. Wai, Dalgleish G. Angus and Galustian Christine, The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy, Current Signal Transduction Therapy 2009; 4 (2) . https://dx.doi.org/10.2174/157436209788167475
DOI https://dx.doi.org/10.2174/157436209788167475 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients
Current Cancer Drug Targets Current and Future Scenario of Immunotherapy for the Treatment of Hepatocellular Carcinoma
Current Cancer Therapy Reviews Tissue Biomarkers for Prostate Cancer Radiation Therapy
Current Molecular Medicine Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Stem Cells and the Side Population Theory: A Critical Review
Current Tissue Engineering (Discontinued) Process Variables and Design of Experiments in Liposome and Nanoliposome Research
Mini-Reviews in Medicinal Chemistry At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Current Molecular Medicine Interaction of Autophagy and Toll-Like Receptors: A Regulatory Cross- Talk - Even in Cancer Cells?
Current Drug Targets Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Current Pharmaceutical Biotechnology Recent Advances of Metallocenes for Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Mitochondrial Respiratory Complex I: Structure, Function and Implication in Human Diseases
Current Medicinal Chemistry Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Emerging Role of Mucins in Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy Oncolytic Virus Therapy - Foreword
Current Cancer Drug Targets Retraction Notice: Current Management of Vomiting After Tonsillectomy in Children
Current Drug Safety Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Current Pharmaceutical Design